PT-141: Research Overview, Mechanism of Action & Lab Supply Standards
A summary of published preclinical and clinical research on PT-141 (Bremelanotide), a melanocortin receptor agonist, including proposed mechanisms, MC3R/MC4R pharmacology, study findings, and sourcing considerations for Canadian researchers.
What Is PT-141?
PT-141 (chemical name: Bremelanotide) is a synthetic cyclic heptapeptide derived from alpha-melanocyte stimulating hormone (α-MSH) and its analogue Melanotan II. Unlike PDE5 inhibitors which act peripherally on vascular smooth muscle, PT-141 acts centrally via melanocortin receptors (MC3R and MC4R) expressed in hypothalamic regions involved in sexual arousal and motivation. This central mechanism of action makes PT-141 a distinct pharmacological tool for studying the neural regulation of sexual behavior.
PT-141 has been the subject of preclinical and clinical research. All material supplied by ACCUTIDE Research Supply is for laboratory and research use only (RUO) and is not intended for human consumption or therapeutic application.
Proposed Mechanisms of Action
MC3R and MC4R Agonism
PT-141 binds melanocortin receptor subtypes 3 and 4 (MC3R and MC4R) in the central nervous system, particularly in the hypothalamus and related limbic structures. Both receptors are Gs-coupled, activating adenylate cyclase and raising intracellular cAMP in target neurons involved in arousal and motivational circuits.
Central vs. Peripheral Mechanism
The principal pharmacological distinction of PT-141 from peripheral vasodilators (PDE5 inhibitors) is its central site of action. Research studies consistently show that PT-141-induced responses are not blocked by peripheral vasodilator antagonists, confirming the neural rather than vascular primary mechanism.
Hypothalamic Arousal Pathways
MC4R is highly expressed in the paraventricular nucleus (PVN) of the hypothalamus, a region critically involved in sexual arousal circuitry. Activation of MC4R in PVN neurons has been linked to downstream oxytocin release and activation of pro-erectile spinal and autonomic pathways in preclinical models.
Dopaminergic System Interaction
Preclinical research has documented cross-talk between melanocortin and dopaminergic systems in the mesolimbic pathway. MC4R activation in the nucleus accumbens and ventral tegmental area has been associated with dopamine release and reward-related behavioral outcomes in rodent studies.
Selected Published Research
The following is a selection of peer-reviewed studies available in PubMed. This is not a comprehensive literature review.
Wessells H, et al. — International Journal of Impotence Research, 2000
Early clinical study demonstrating PT-141's ability to induce erectile response via central melanocortin receptor activation, distinguishing its mechanism from peripheral PDE5-based pathways.
Diamond LE, et al. — Journal of Sexual Medicine, 2004
Randomized crossover clinical trial evaluating PT-141 in men with erectile dysfunction, documenting dose-dependent improvements in erectile function scores relative to placebo via central melanocortin pathway activation.
Pfaus JG, et al. — Annual Review of Sex Research, 2007
Review of preclinical and clinical research on MC3R and MC4R receptor involvement in sexual arousal, motivation, and behavior, with discussion of melanocortin agonist pharmacology and brain region-specific activity.
King SH, et al. — Peptides, 2007
Reviews the role of the central melanocortin system in regulating sexual function, covering MC3R and MC4R receptor distribution in hypothalamic nuclei, downstream signaling, and the pharmacological basis of melanocortin agonist activity in sexual arousal models.
Purity Standards for Research Use
HPLC Purity Analysis
Research-grade PT-141 should meet ≥99%+ purity by HPLC. The cyclic peptide structure of PT-141 requires careful purity analysis to confirm absence of linear or partially cyclized impurities that would alter receptor binding characteristics.
Mass Spectrometry (Identity)
MS confirms the correct molecular weight (MW 1025.2 Da) and cyclic structure of PT-141, distinguishing it from related melanocortin peptides such as Melanotan II and α-MSH.
Endotoxin Testing
LAL endotoxin testing is critical for central nervous system research models. Endotoxin crosses the blood-brain barrier at high concentrations and activates neuroinflammatory pathways that can confound behavioral and neuroendocrine study endpoints.
Certificate of Analysis (COA)
Batch-specific COA documenting HPLC purity, MS identity, and endotoxin results. Required for institutional procurement and for correlating experimental behavioral outcomes with source material quality.
Sourcing PT-141 in Canada
ACCUTIDE Research Supply provides PT-141 tested to ≥99%+ HPLC purity with batch-specific COA documentation. All material is lyophilized for stability and ships Canada-wide. For research use only.
PT-141 — Canadian Research Supply
HPLC tested · COA every batch · Ships Canada-wide · RUO
Often Researched With
Compounds frequently co-investigated alongside Pt-141 in preclinical research literature.
Cytoprotective peptide co-investigated with melanocortin compounds in CNS and vascular research.
Melanocortin-derived anti-inflammatory peptide — shares receptor family lineage with PT-141.
Anxiolytic neuropeptide co-investigated with PT-141 in behavioral and CNS preclinical models.
Research Use Only Disclaimer: All information on this page is provided for scientific research and educational purposes only. PT-141 supplied by ACCUTIDE Research Supply is strictly for laboratory and research use (RUO). It is not intended for human or animal consumption, therapeutic use, or any application outside of controlled research settings. Findings must not be extrapolated to human use.